372 related articles for article (PubMed ID: 33159505)
1. Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy.
Kanjanapan Y; Yip D
Cancer Med; 2020 Dec; 9(23):9027-9035. PubMed ID: 33159505
[TBL] [Abstract][Full Text] [Related]
2. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
3. Infectious complications in patients treated with immune checkpoint inhibitors.
Karam JD; Noel N; Voisin AL; Lanoy E; Michot JM; Lambotte O
Eur J Cancer; 2020 Dec; 141():137-142. PubMed ID: 33137589
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
5. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; EcheverrÃa M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
6. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
7. The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids.
Shah NJ; Cook MR; Wu T; Lev-Ari S; Blackburn MJ; Serzan MT; Alaoui A; Ahn J; Atkins MB
J Natl Compr Canc Netw; 2022 Jul; 20(7):800-807.e1. PubMed ID: 35830888
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
9. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
10. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
12. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
[TBL] [Abstract][Full Text] [Related]
13. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
[TBL] [Abstract][Full Text] [Related]
14. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
[TBL] [Abstract][Full Text] [Related]
15. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
16. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.
Stroh GR; Peikert T; Escalante P
Cancer Immunol Immunother; 2021 Nov; 70(11):3105-3111. PubMed ID: 33770211
[TBL] [Abstract][Full Text] [Related]
17. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
18. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
19. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
